证券代码：688289 证券简称：圣湘生物 公告编号：2025-046 圣湘生物科技股份有限公司 关于召开2025年第三次临时股东大会的 通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 7 月 29 日 2025年第三次临时股东大会 召开日期时间：2025 年 7 月 29 日 14 点 30 分 召开地点：上海市闵行区华西路 680 号（圣湘生物上海产业园） 至2025 年 7 月 29 日 股东大会召开日期：2025年7月29日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东 ...

圣湘生物科技股份有限公司（以下简称"公司"）第二届监事会 2025 年第五次临 时会议于 2025 年 7 月 10 日以现场方式召开，会议通知已于 2025 年 7 月 7 日以书面 方式送达全体监事。会议由监事会主席谭寤女士主持，应出席监事 3 人，实际出席监 事 3 人。本次会议的通知、召开及审议程序符合《中华人民共和国公司法》（以下简 称"《公司法》"）和《公司章程》的有关规定。 证券代码：688289 证券简称：圣湘生物 公告编号：2025-042 圣湘生物科技股份有限公司 第二届监事会 2025 年第五次临时会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 表决结果：同意 3 票，反对 0 票，弃权 0 票。 二、监事会会议审议情况 经与会监事审议，一致通过如下议案： 1、审议通过了《圣湘生物科技股份有限公司关于<公司 2025 年限制性股票激励 计划（草案）>及其摘要的议案》 具体内容详见公司同日刊登于上海证券交易所网站（www.sse.com.cn）的《圣湘 生物科技股份 ...

3、《激励计划（草案）》的制定、审议流程和内容符合《公司法》《证券法》 《管理办法》《上市规则》等有关法律、法规及规范性文件的规定；对各激励对 象限制性股票的授予安排、归属安排（包括授予数量、授予日期、授予条件、授 予价格、任职期限、归属条件、归属日等事项）未违反有关法律、法规的规定， 未侵犯公司及全体股东的利益。本激励计划的相关议案尚需提交公司股东大会审 议通过后方可实施。 4、公司不存在向激励对象提供贷款、贷款担保或任何其他财务资助的计划 或安排。 圣湘生物科技股份有限公司（以下简称"公司"）董事会薪酬与考核委员会依 据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券 法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管 理办法》"）、《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、 《科创板上市公司自律监管指南第 4 号——股权激励信息披露》等相关法律、法 规及规范性文件和《圣湘生物科技股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，对《公司 2025 年限制性股票激励计划（草案）》（以下简称"《激励 计划（草案）》"或"本激 ...

证券代码：688289 证券简称：圣湘生物 公告编号：2025-041 圣湘生物科技股份有限公司 第二届董事会 2025 年第八次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 圣湘生物科技股份有限公司（以下简称"公司"）第二届董事会 2025 年第八次 临时会议于 2025 年 7 月 10 日以现场结合通讯方式召开，会议通知已于 2025 年 7 月 7 日以邮件方式送达全体董事。会议由董事长戴立忠先生主持，应出席董事 11 人，实 际出席董事 11 人。会议的通知、召开及审议程序符合《中华人民共和国公司法》（以 下简称"《公司法》"）和《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事审议，一致通过如下议案： 1、审议通过了《圣湘生物科技股份有限公司关于<公司 2025 年限制性股票激励 计划（草案）>及其摘要的议案》 内容：为进一步完善公司法人治理结构，建立、健全公司长效激励约束机制，吸 引和留住公司全资子公司中山圣湘海济生物医药有限公司的核心骨干员工，充分调动 ...

Group 1 - The core business of the company is to provide integrated in vitro diagnostic solutions centered on self-innovated gene technology, including diagnostic reagents, instruments, and third-party medical testing services [2] - The company has significantly enhanced its brand recognition and industry position, receiving high recognition and honors from authoritative institutions both domestically and internationally [2] - The latest quarterly report shows that in Q1 2025, the company achieved an operating income of 475 million yuan, a year-on-year increase of 21.62%, and a net profit of 91.73 million yuan, a year-on-year increase of 13.22%, with a gross profit margin of 76.71% [2] Group 2 - As of March 31, 2025, the company had 20,629 shareholders, an increase of 205 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company's current price-to-earnings (PE) ratio is 41.73, which is lower than the industry average of 51.42 and the industry median of 37.44, ranking 83rd in the industry [1][3] - The company has been listed in the global top 100 medical device companies for two consecutive years and has received various national and provincial recognitions [2]

Core Viewpoint - The A-share market shows a slight decline with the Shanghai Composite Index at 3468.65 points, down by 0.11%, while the total trading volume reached 584.993 billion yuan, indicating a mixed performance in the market [1]. Group 1: Market Performance - As of 10:29 AM, the Shanghai Composite Index is at 3468.65 points, with a decrease of 0.11% [1]. - The total trading volume in the A-share market is 584.993 billion yuan [1]. Group 2: Stocks Breaking the Annual Line - A total of 46 A-shares have surpassed the annual line today, with notable stocks including Guotou Zhonglu, Jigaofazhan, and Huate Gas, showing significant deviation rates of 8.45%, 6.51%, and 4.34% respectively [1]. - Stocks with smaller deviation rates that have just crossed the annual line include Pudong Jinqiao, Hengli Petrochemical, and Zhenyou Technology [1]. Group 3: Top Stocks by Deviation Rate - The top three stocks with the highest deviation rates are: - Guotou Zhonglu (Code: 600962) with a price increase of 9.98% and a deviation rate of 8.45% [1]. - Jigaofazhan (Code: 600807) with a price increase of 10.16% and a deviation rate of 6.51% [1]. - Huate Gas (Code: 688268) with a price increase of 4.36% and a deviation rate of 4.34% [1]. Group 4: Additional Stocks with Positive Performance - Other notable stocks with positive performance include: - Jingtou Fazhan (Code: 600683) with a price increase of 4.39% and a deviation rate of 2.45% [1]. - Huaihe Energy (Code: 600575) with a price increase of 2.23% and a deviation rate of 1.96% [1]. - ST Gaosi (Code: 002848) with a price increase of 2.88% and a deviation rate of 1.65% [1]. Group 5: Stocks with Lower Deviation Rates - Stocks with lower deviation rates that have recently crossed the annual line include: - Qianyuan Qian (Code: 600189) with a price increase of 1.80% and a deviation rate of 0.82% [2]. - Sifang Stock (Code: 601126) with a price increase of 0.79% and a deviation rate of 0.72% [2]. - Wentai Technology (Code: 600745) with a price increase of 0.94% and a deviation rate of 0.66% [2].

Group 1 - The core business of the company is to provide integrated in vitro diagnostic solutions centered on independent innovation in gene technology, including diagnostic reagents, instruments, and third-party medical testing services [2] - The company has significantly enhanced its brand recognition and industry position, receiving high recognition and honors from authoritative institutions both domestically and internationally [2] - The company has been listed in the global top 100 medical device companies for two consecutive years and has received various national and provincial certifications [2] Group 2 - As of March 31, 2025, the company had 20,629 shareholders, an increase of 205 from the previous period, with an average holding value of 352,800 yuan and an average holding of 27,600 shares per shareholder [1] - The company's latest quarterly report for Q1 2025 shows a revenue of 475 million yuan, a year-on-year increase of 21.62%, and a net profit of 91.73 million yuan, a year-on-year increase of 13.22%, with a gross profit margin of 76.71% [2] - The company's rolling price-to-earnings (PE) ratio is 41.00, compared to the industry average of 49.45 and the industry median of 35.92, ranking 85th in the medical device industry [1][3]

Group 1 - The company, Shengxiang Biotechnology Co., Ltd., has received medical device registration certificates for its nucleic acid detection kits for Pneumocystis jirovecii, Cryptococcus neoformans, and Aspergillus species from the National Medical Products Administration [1] - Invasive pulmonary fungal disease (IPFD) is a significant public health threat, characterized by acute or chronic tissue damage due to fungal invasion, with common pathogens including Aspergillus, Cryptococcus neoformans, and Pneumocystis jirovecii [1] - The incidence of IPFD is rising, necessitating efficient laboratory testing methods to aid in timely diagnosis and treatment, thereby improving patient survival rates [1] Group 2 - The newly certified detection products utilize real-time fluorescent PCR technology, which offers higher sensitivity and efficiency compared to traditional methods such as microscopy, culture, and serology [2] - The product can simultaneously detect three high-risk pulmonary fungal pathogens, enhancing the company's respiratory product ecosystem and providing more effective diagnostic solutions for clinical settings [2] - The approval of these products is expected to contribute positively to the company's offerings, although future performance will depend on market expansion efforts, brand influence, and actual market demand [2]

证券代码：688289 证券简称：圣湘生物 公告编号：2025-040 侵袭性肺真菌病（invasive pulmonary fungal disease，IPFD）是一种由真菌直接侵 入肺组织或支气管所引起的急性或慢性组织病理损伤性疾病。曲霉、新型隐球菌和耶 氏肺孢子菌是其三大常见致病菌。IPFD 患者通常病情较重，疾病进展快、但临床和 影像学表现不典型，易误诊和漏诊，导致临床救治率低、死亡率高、医疗负担重，是 公共卫生的一大威胁。近年来，IPFD 发病率还在不断上升，临床亟需高效精准的实 验室检测方法辅助临床及时明确诊断，进而及时治疗，提高患者救治率。 相较镜检、培养和血清学等既往检测方法，PCR 检测技术敏感性更高、特异性更 强，可有效提高检测效率、降低使用成本，对于亟需快速明确病原的真菌感染的早期 诊断具有重要价值，目前已被国内外指南推荐用于侵袭性真菌病的诊断。 公司本次获证的检测产品采用实时荧光 PCR 技术，一次检测即可覆盖耶氏肺孢 子菌、新型隐球菌、曲霉三大高危肺部真菌病原体，产品灵敏度及检测效率更高，进 一步丰富了公司呼吸道类产品生态，可为临床提供更高效精准的检测方案，为患者争 取更多宝贵治疗 ...

圣湘生物公告，公司产品耶氏肺孢子菌、新型隐球菌、曲霉核酸检测试剂盒(荧光PCR法)近日获得国家 药品监督管理局颁发的《医疗器械注册证》，注册类别为境内第三类体外诊断试剂，注册证有效期至 2030年6月19日。该产品用于体外定性检测人痰液、肺泡灌洗液中深部感染真菌，包括耶氏肺孢子菌、 新型隐球菌和曲霉DNA核酸。产品采用实时荧光PCR技术，一次检测即可覆盖三大高危肺部真菌病原 体，进一步丰富了公司呼吸道类产品生态，为临床提供更高效精准的检测方案。 ...